Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative

This page shows the latest neurodegenerative news and features for those working in and with pharma, biotech and healthcare.

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Fox Foundation (MJFF) for an imaging approach that will be used to develop NLRP3 drugs for Parkinson’s and other neurodegenerative diseases.

Latest news

More from news
Approximately 7 fully matching, plus 108 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

  • Biogen appoints executive VP, corporate development Biogen appoints executive VP, corporate development

    to expand the company's portfolio of therapies for people living with serious neurodegenerative diseases.”.

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    Francois Nader joins the biotech. Prevail Therapeutics, a biotechnology company focused on the development of gene therapies for patients with neurodegenerative diseases, has strengthened its board of directors with the addition ... The Prevail team has

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Novartis’ Michael Ryan joins the neurodegenerative diseases specialist. Lausanne, Switzerland-based Asceneuron has appointed Michael Ryan as its new chief medical officer. ... He joins the neurodegenerative diseases specialist from Novartis, where he

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    Prof De Strooper is currently a professor of molecular medicine at the University of Leuven and leads its laboratory for the research of neurodegenerative diseases.

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Dr Mikael Dolsten, president of worldwide research and development at Pfizer, said: “Dr Isacson's deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer's and

More from appointments
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • Conference Live: Case study

    The challenge:. Our client was developing a portfolio for the treatment of a chronic neurodegenerative disease and planned to have a significant presence at key neuroscience conferences over the coming year.

  • Alzheimer's and Brain Awareness Month

    AD is a neurodegenerative disease, meaning that its symptoms are generally mild at the start, but become progressively worse over time, eventually interfering with the everyday life of those affected.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics